LOL Your argument is that NWBO would only treat and get revenue for $200M a year in the UK.... Okay. That would easily give an evaluation of Market Cap of $>$2B which is $1 to $2 dollars a share. AND THAT IS FOR THE UK ALONE.
RIGHT! No one from the US will go to the UK to pay for a possible life saving treatment not offered in the US. Funny how there are already US patients paying out of pocket. ALSO WITH MHRA APPROVAL, THE FDA WILL BE PRESSURED BY HOSPITALS AND PATIENTS IF THEY DONT OFFER DCVAX BUT THE REST OF THE WORLD DOES.... There are many fast tracks through MHRA approval both to Canada and the US. I DIDNT EVEN INCLUDE CANADIAN NUMBERS!!
The best is your argument that they would only get maybe $200M but yeah its not worth the investment.... LOL
You are missing the reason the MAA would not be approved before the leukapheresis expansion and changed plans for Class B clean room space being set aside for Class C clean room space for use with Flaskworks. No way the MAA approval would have come before that change was made due to plans to expand IFRs to cancer from GBM. You just don’t understand the obvious give and take going on here before the MAA is finalized. For those thinking that a proper manufacturing preparedness plan for the big picture is not part of this, the guidance and role of MHRA to address all manufacturing concerns is either beyond your understanding or doesn’t square with your purpose for stating otherwise. Best wishes.
Market Data 
Markets 
AI
